LiquidHALLMARK -Next-generation Sequencing (NGS) Assay for Ultrasensitive Biomarker Detection

LiquidHALLMARK® is an ultrasensitive next-generation sequencing assay for genomic profiling of a patient’s unique cancer. By requiring only a single blood sample, LiquidHALLMARK provides important information for cancer care especially when tissue by invasive biopsy is insufficient or inaccessible.

Most popular related searches

advanced sequencing

genomic profile

LiquidHALLMARK is a comprehensive, amplicon-based NGS assay for ultrasensitive biomarker detection.

Powered by our proprietary amplicon-based sequencing technology, LiquidHALLMARK examines plasma circulating tumor DNA (ctDNA) mutations in 80 genes, including fusions in 10 genes.

LiquidHALLMARK targets genes that are commonly associated with the 15 cancers, including lung, breast and colon cancer.

LiquidHALLMARK -Next-generation Sequencing (NGS) Assay for Ultrasensitive Biomarker Detection

Details

Performance Specifications